SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.

MLA

Wang, Ying-Ting, et al. “SARS-CoV-2 Monoclonal Antibodies with Therapeutic Potential: Broad Neutralizing Activity and No Evidence of Antibody-Dependent Enhancement.” Antiviral Research, vol. 195, Nov. 2021, p. 105185. EBSCOhost, https://doi.org/10.1016/j.antiviral.2021.105185.

APA

Wang, Y.-T., Allen, R. D., 3rd, Kim, K., Shafee, N., Gonzalez, A. J., Nguyen, M. N., Valentine, K. M., Cao, X., Lu, L., Pai, C.-I., Johnson, S., Kerwin, L., Zhou, H., Zhang, Y., & Shresta, S. (2021). SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement. Antiviral Research, 195, 105185. https://doi.org/10.1016/j.antiviral.2021.105185

Chicago

Wang, Ying-Ting, Robert D Allen 3rd, Kenneth Kim, Norazizah Shafee, Andrew J Gonzalez, Michael N Nguyen, Kristen M Valentine, et al. 2021. “SARS-CoV-2 Monoclonal Antibodies with Therapeutic Potential: Broad Neutralizing Activity and No Evidence of Antibody-Dependent Enhancement.” Antiviral Research 195 (November): 105185. doi:10.1016/j.antiviral.2021.105185.